In addition to the changing technology used by the NHS Bowel Cancer Screening Programmes, FIT is rapidly becoming more popular as a triage tool for patients presenting with abdominal symptoms, reducing the immediate need for colonoscopy investigations. Here, Callum G Fraser explores the need for low faecal haemoglobin concentration estimates.
Faecal immunochemical tests (FITs) for haemoglobin are now widely used in asymptomatic screening for bowel cancer and in assessment of patients presenting with lower bowel symptoms. The FIT might also be of value in other clinical settings such as surveillance of patients with previous bowel disease. Quantitative FIT provides estimates of faecal haemoglobin (f-Hb) concentration for use in all of these cases.
It is now well documented that the f-Hb is related to the severity of bowel disease. Thus, lowering the f-Hb cut-off used to trigger clinical action confers better detection of bowel cancer, adenoma and other serious bowel pathology. The clinical sensitivity increases, but the positivity rises, the demand for colonoscopy increases, the number of false-positive results rises, and the positive predictive value falls.
As a number of users of FIT in assessment of symptomatic patients see cancer detection as the most important role, there is considerable interest in using very low f-Hb as a cut-off. In addition, those wishing to use FIT as a rule-out test to reassure those patients who are unlikely to have significant bowel disease are also interested in using very low f-Hb cut-off, in order to minimise the chances of missing disease. So, the question for both approaches is “how low can FIT go?”
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.